ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a ...

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and ...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically ...

CSL Seqirus to provide pandemic influenza vaccine to support 17 EU and EEA countries and the EU Commission in the event of a pandemic declaration. The decision by the Health Emergency Preparedness ...

ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...

ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the first-in-class monoclonal ...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional ...

Melbourne, 4 March 2025 – CSL Seqirus and Esperion Therapeutics have today announced the signing of an exclusive license and distribution agreement to commercialize Nexletol ® (bempedoic acid) and ...

ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY, reinforcing CSL ...

ANDEMBRY ® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation ...

"ANDEMBRY is a significant advancement in the management of hereditary angioedema, offering people living with this life-threatening condition long-term control over their disease with a ...